#Acquisition #Ireland #Dublin #Theravance Biopharma #Zymeworks

Major Acquisition Announcement: Theravance Biopharma and Zymeworks

In a landmark decision for the biotechnology sector, Theravance Biopharma, Inc. has declared a definitive agreement that will see it acquired by Zymeworks Inc. The agreement stipulates that shareholders will receive $17.00 per share in cash, which translates to an equity value of around $929 million. This acquisition not only promises immediate returns for shareholders but also introduces a mechanism for future revenue through a Contingent Value Right (CVR).

Details of the Acquisition

The acquisition is set to provide Theravance Biopharma shareholders with substantial cash earnings in addition to the CVR. This right entitles them to receive 80% of the net proceeds stemming from any future licensing or monetization of the drug ampreloxetine over the next decade. The remaining 20% will benefit Zymeworks.

This offer represents a notable premium of 22% compared to Theravance’s closing stock price on March 3, 2026, which coincided with the announcement of encouraging results from the Phase 3 CYPRESS study of ampreloxetine. The acquisition follows a thorough strategic review conducted by the company's Board of Directors, which evaluated a myriad of options to enhance shareholder value.

Strategic Review Process

The Strategic Review Committee has been active since 2024 and, along with financial advisors from Lazard, assessed several strategies. These included not just this acquisition, but also the monetization of the company’s TRELEGY® royalty interest in a transaction worth $225 million in 2025. They meticulously considered various directions, concluding that the agreement with Zymeworks was in the best interest of the company's future.

Susannah Gray, the independent Chair of the Board, expressed her confidence in the transaction, emphasizing that it acknowledges the intrinsic value of Theravance's assets. Among these assets is the company’s interest in YUPELRI®, a vital product for COPD patients, and the potential milestone payments expected from TRELEGY®.

Leadership Insights

Rick E Winningham, CEO of Theravance Biopharma, highlighted the accomplishments the company has achieved, particularly the successful launch of YUPELRI®, which is now a valued treatment for chronic obstructive pulmonary disease (COPD). He also mentioned ongoing efforts to explore opportunities to develop ampreloxetine for conditions like Multiple System Atrophy (MSA) and Neurogenic Orthostatic Hypotension (nOH), which currently lack effective treatments.

Transaction Predictions

With the transaction expected to finalize in the latter half of 2026, it remains contingent upon shareholder approval and regulatory clearances. The Board of Directors has unanimously supported the agreement and encourages shareholders to endorse it. As part of this process, a new designee from Theravance will seek potential opportunities related to ampreloxetine on behalf of Zymeworks, should no transactions be finalized prior to deal closure.

Lazard and Evercore are both acting as financial advisors for Theravance, while legal representatives include Skadden, Arps, Slate, Meagher & Flom LLP for Theravance and Kirkland & Ellis LLP for Zymeworks.

Future of Theravance Biopharma

This acquisition encapsulates a significant shift in how biotechnology firms can position themselves for future growth while maximizing shareholder returns. By securing this deal with Zymeworks, Theravance Biopharma not only reinforces its financial stability but bolsters its chances to leverage the potential success of ongoing and new pharmaceutical developments. As the landscape evolves, stakeholders in Theravance can look forward to a promising new chapter under Zymeworks’ stewardship, highlighting the importance of strategic collaborations in the biomedical realm.